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Available online 17 July 2016Statins are 3-hydroxy-3-methylglutaryl coenzymeA (HMG-CoA) reductase (HMGR) inhibitors decreasing serum
cholesterol and have shown promise in cancer prevention. In this study, we demonstrated the oncogenic role of
HMGR in colorectal cancer (CRC) by disclosing increased HMGR activity in CRC patients and its enhancement of
anti-apoptosis and stemness. Our previous studies showed that statins containing carboxylic acid chains pos-
sessed activity against histone deacetylases (HDACs), and strengthened their anti-HDAC activity through design-
ing HMGR-HDAC dual inhibitors, JMF compounds. These compounds exerted anti-cancer effect in CRC cells as
well as in AOM-DSS and ApcMin/+ CRC mouse models. JMF mostly regulated the genes related to apoptosis and
inﬂammation through genome-wide ChIP-on-chip analysis, and Ingenuity Pathways Analysis (IPA) predicted
their respective regulation by NR3C1 and NF-κB. Furthermore, JMF inhibitedmetastasis, angiogenesis and cancer
stemness, and potentiated the effect of oxaliplatin in CRCmouse models. Dual HMGR-HDAC inhibitor could be a
potential treatment for CRC.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
(HMGR) is the rate-limiting enzyme for cholesterol synthesis in the con-
version of HMG-CoA tomevalonate. Statins are HMGR inhibitors decreas-
ing serum cholesterol to reduce the incidence of cardiovascular and
cerebrovascular disorders (Minder et al., 2012). In addition to cholesterol
synthesis, activation of HMGR facilitated protein prenylation, such as
farnesylation of Ras oncoproteins for cell growth and carcinogenesis
(Thurnher et al., 2012). The mevalonate pathway was up-regulated by
mutant p53 or activation of oncogenic signaling, such as HIF-1 or PI3K-
Akt (Freed-Pastor et al., 2012; Semenza, 2003; Yuan and Cantley, 2008).
Clinical studies also showed the promise of statins in cancer preventionest.
y, College ofMedicine, National
0018, Taiwan.
en).
. This is an open access article under(Simon et al., 2012; Poynter et al., 2005). Therefore, targeting HMGR-
mevalonate pathway might be a strategy against cancer. However, the
role of HMGR as an oncotarget remains to be elucidated.
Our previous studies demonstrated that statins containing carboxyl-
ic acid chains also had activity against histone deacetylase (HDAC), an
important oncoprotein, to exert anti-cancer effects. Thus, statins may
suppress tumor formation through the inhibition of both HMGR and
HDAC activity (Lin et al., 2008). To further improve statins' activity
against HDAC, three statin hydroxamates named compound 12, 13,
and 14 as respective JMF3086, 3171, and 3173 were designed to inhibit
class I and II HDACs andHMGR (Chen et al., 2013), and their anti-cancer
activities were explored. Recently, the strategy of developing
polypharmacological molecules that dually inhibit HDACs and other
therapeutic targets has been reported (Falkenberg and Johnstone,
2014). Accordingly, whether dual targeting HMGR and HDAC is a strat-
egy for treating cancer deserves further investigation.
Colorectal cancer (CRC) is a worldwide cancer with a rising annual
incidence, leading to a signiﬁcant mortality due to metastasis.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Targeting HMG-CoA reductase in colorectal cancer cells and the effect of JMF compounds on cell viability and apoptosis. (A) HMGR activity in CRC tissues from patients (T)
normalized to adjacent normal epithelium (N) is shown. The HMG-CoA reductase activity was measured according to NADPH oxidation by HMGR in the presence of the substrate
HMG-CoA using an assay kit (CS-1090). 100 μg protein of tissue was mixed with NADPH and HMG-CoA (substrate), and incubated at 37 °C for 5 min. The absorbance at 340 nm was
measured, and the decrease in A340 absorbance represented the oxidation of NADPH by the catalytic subunit of HMGR in the presence of the substrate HMG-CoA. The SPSS program
(SPSS Inc.) was used for all statistical analysis, which was performed by two-sided Student's t-test. ⁎⁎P b 0.01. (B) Western blot analysis for HMGR expression in CRC cells. (C) Effect of
HMGR knockout on MCL1 expression in HCT116 cells by CRISPR technology (left panel). Effect of HMGR knockdown on MCL1, BAX and cleaved-caspase-3 expressions in HCT116 cells
by shHMGR transfection (right panel). The suspension and attached cells were harvested. (D) HMGR-knockout stable clones were treated with different doses of mevalonate for
5 days and the cell viability was analyzed by MTT assay. ##P b 0.01 versus vector; ⁎P b 0.01 versus 0 mMmevalonate. (E) Effect of overexpressed HMGR on MCL1 and COX-II after 48 h
in SW480 cells. (F) Structure of the statin hydroxamates was shown. (G) Effect of three statin hydroxamates and the corresponding statins on the cell viability of various human
cancer cell lines. The half maximal inhibitory concentration (IC50) values for individual cell lines are presented. Cells were treated with various concentrations of test compounds for
72 h, and cell viability was measured by the MTT assay. (H) HCT116 cells were treated with the indicated doses of test compounds for 72 h, and cell viability was measured by the
MTT assay. ⁎⁎P b 0.01 versus control; #P b 0.05 and ##P b 0.01. (I) Effect of JMF3086 on the cell cycle distribution of HCT116 cells. Cells were treated with 10–50 μM JMF3086 for 24 h
and analyzed by ﬂow cytometry. (J) HCT116 cells were treated with 10 or 50 μM JMF3086 for 24 h, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
staining was performed to detect apoptotic cells. Original magniﬁcation: 400×. (K) Dose- and time-dependent effects of JMF3086 on the expression of apoptosis-related proteins in
HCT116 cells. Cells were treated with 10–50 μM JMF3086 for 24 h, or treated with 10 μM JMF3086 for 24–72 h. Total cell lysates were prepared, and Western blotting was performed.
125T.-T. Wei et al. / EBioMedicine 10 (2016) 124–136Metastatic CRC (mCRC) is an incurable disease requiring systemic drug
therapy to prolong the survival of patients. Although stepwise discovery
of chemotherapeutic and molecular targeted agents has improved the
survival of patientswithmCRC from12 to 24months in the past twode-
cades (Meyerhardt and Mayer, 2005), inevitably, emerged acquired re-
sistance ultimately leads tomortality. This introduces an unmetmedical
need for the discovery of new drugs. Therefore, the development of
drugs with different mechanisms to avoid cross-resistance is crucial to
further prolong the survival of patients with mCRC.Fig. 2. Genome-wide analysis of target genes in JMF3086-treated HCT116 colorectal cance
immunoprecipitated with control rabbit IgG or anti-H3K27-Ac antibody. ChIP-on-chip assays w
log-ratios were analyzed by Gene Ontology (GO). The most signiﬁcant biological functions re
working model (upper left panel). Ingenuity Pathways Analysis (IPA) predicted that the gen
predicted inﬂammatory genes were regulated by NF-κB. The molecular network has a P-score
ratio are shown in green, while those with two-fold upregulation are shown in red. (D) ChIP-
anti-CBP, anti-HDAC1, or anti-HDAC3 antibodies to detect their differential binding to the pro
PCR and plotted as percent (%) of input DNA. ⁎P b 0.05, ⁎⁎P b 0.01 versus basal, two-sided StudIn this study, we demonstrated that HMGR activity was increased in
CRC patients and veriﬁed as an oncotarget through knockout by CRISPR
and knockdown by shRNA in HMGR-high-expressing HCT116 cells, and
overexpression in HMGR-low-expressing SW480 cells. Furthermore,
HMGR enhanced the stemness of CRC. JMF3086 most regulated the
genes in CRC cells related to apoptosis and inﬂammation through a ge-
nome-wide ChIP-on-chip analysis categorized by Gene Ontology (GO).
Ingenuity Pathways Analysis (IPA) analysis further predicted their re-
spective regulation by NR3C1 and NF-κB. JMF3086 down-regulatedr cells. The cell lysates from HCT116 cells treated with 30 μM JMF3086 for 24 h were
ere performed, and genes with more than two-fold decrease or increase in H3K27-Ac in
gulated by JMF3086 were apoptosis and inﬂammation (A–C). (A) Schematic overview of
es associated with apoptosis were regulated by NR3C1. P = 4.30E-37. (B) IPA analysis
(−log10 (P-value)) of 48. (C) Genes with two-fold downregulation of H3K27-Ac in log-
qPCR was performed by immunoprecipitation with control rabbit IgG or anti-H3K27-Ac,
moters of TNF-α, CD166, COX-II, BCL-2, TIMP3, and BMP2. Data were analyzed by the Q-
ent t-test.
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128 T.-T. Wei et al. / EBioMedicine 10 (2016) 124–136inﬂammatory and stemness genes and up-regulated tumor suppressor
genes. JMF3086 exhibited therapeutic beneﬁts against azoxymethane-
dextran sulfate sodium (AOM-DSS) CRC and inﬁltrations of macro-
phages and neutrophils in mice, and inhibited tumor progression in
ApcMin/+ mice as well as inhibiting themetastatic ability of CRC and an-
giogenesis. Furthermore, JMF3086 inhibited the stemness of CRC and
potentiated the anti-cancer effect of oxaliplatin in vitro and in vivo.
Our data provides compelling evidence that HMGR is an oncotarget of
CRC and the polypharmacological HDAC inhibitors-statin hydroxamates
we have developed exert signiﬁcant therapeutic beneﬁts in preclinical
models and are promising drugs for CRC treatment.2. Methods
2.1. Patients and Tumor Specimens
Paired tumor and control tissue sampleswere collected from 13 CRC
patientswhounderwent surgical resection atNational TaiwanUniversi-
ty Hospital between 2010 and 2011. The control samples were from the
normal mucosa adjacent to tumors. All samples were stored at−80 °C.
The Institutional Review Board of the National Taiwan University
Hospital approved the procedures for tissue collection and analysis,
and written informed consent was obtained from each patient.2.2. Mice
C57BL/6, BALB/c and NOD/SCID mice were obtained from the
National Laboratory Animal Center (Taiwan). Experiments on mice
were performed in accordance with protocols approved by the Institu-
tional Animal Care and Use Committee (IACUC) of the College of Medi-
cine, National Taiwan University.
The B6.Rcc.B6J-ApcMin/Cnrm males were purchased from The
European Mouse Mutant Archive (EMMAID: 02000; München, Germa-
ny). ApcMin/+ mice were produced and maintained by breeding ApcMin/
+ males with C57BL/6 female mice.2.3. Chromatin Immunoprecipitation (ChIP) and ChIP-on-chip Assays
HCT116 cells were treated with 30 μM JMF3086 for 24 h, and ChIP
assays using control Rabbit IgG (sc-2027; Santa Cruz) or anti-H3K27-
ac antibodies (#4353; Cell Signaling) were performed as previously de-
scribed (Chou et al., 2011). ChIP-on-chip assays were performed in the
Microarray and Gene Expression Analysis Core Facility of the National
Yang-Ming University VGH Genome Research Center in Taiwan using
the SurePrint G3 Human Promoter 1 × 1 M Kit (Agilent Technologies)
after DNA was further puriﬁed through phenol-chloroform-isoamyl al-
cohol extraction and ethanol precipitation. Genes with two-fold down-
regulation or upregulation of H3K27-Ac in log-ratio after JMF3086
treatment were regarded signiﬁcant.Fig. 3.Therapeutic effect of JMF compounds on colitis-induced colorectal cancer andApcMin/+mo
days a week for three weeks following the AOM-DSS treatment. (A) Schematic overview of the
arrowhead indicates macroscopic polyps (middle panel). Scale bars: 5 mm. The number of tum
Colon sections were counterstained with H&E, and high-magniﬁcation images of the black-box
were stained by TUNEL assay to detect apoptotic cells. The insets indicated by arrows show hig
1000×). (D) Q-PCR analysis of NR3C1 mRNA expression normalized to GAPDH in colon tissues
sections were immunostained with anti-F4/80, anti-Ly-6G, or anti-COX-II antibodies. Scale
macroscopic lesions. Scale bars: 5 mm. Colon sections were counterstained with H&E. Scale ba
and ⁎⁎P b 0.01 versus vehicle. Colon sections were immunostained with anti-F4/80, or anti-Ly-
II, and cyclin D1 mRNA levels were quantiﬁed by Q-PCR, and the levels of mRNA were no
⁎⁎P b 0.01 versus vehicle; two-sided Student t-test. (H) HMGR and HDAC activities in cell ly
versus vehicle. (I) Therapeutic effect of JMF3086 on ApcMin/+ mice. Schematic overview of the
colon (lower panel) are shown. Scale bars: 5 mm. The sections were counterstained with H&
intestine and colon in ApcMin/+ mice are graphed. ⁎P b 0.05 and ⁎⁎P b 0.01 versus vehicle.2.4. Animal Models for AOM-DSS-induced CRC
CRC was induced by intraperitoneal injection of AOM (12.5 mg/kg)
in conjunction with the DSS stimulus, resulting in tumor development
restricted to the colon in mice as previously described (Yang et al.,
2013). Mice were maintained with a regular diet and drinking water
for 7 days and then subjecting to 3 cycles of DSS treatment, with each
cycle consisting of the administration of 3.5% DSS for 5 days followed
by a 14-day recovery period with regular water (Fig. 3A). Body weight,
the presence of occult or gross blood in the rectum, and stool consisten-
cywere determined daily in themice. Weight change during the exper-
iment was calculated as the percent change in weight compared with
the baseline measurement. Bleeding was scored as 0 when there was
no blood in the Hemoccult test, 1 for a positive Hemoccult result, 2 for
slight bleeding, or 3 for gross bleeding. Regarding stool consistency, 0
points were given for well-formed pellets, 1 point for semi-formed
stools that did not adhere to the anus, 2 points for pasty stools, and 3
points for liquid stools that adhered to the anus. This model is widely
utilized to recapitulate human CRC because it results in inﬂammation
and ulceration of the entire colon, similar towhat is observed in patients
(Ullman and Itzkowitz, 2011). Test compounds were orally adminis-
tered 5 days a week for 3 weeks following the AOM-DSS treatment.
2.5. Animal Model for Experimental Colorectal Cancer Lung Metastasis
HCT116 cells (2 × 106) were injected intravenously into the tail vein
of ﬁve-week-old female nude BALB/c mice. After two weeks, the mice
were treated orally with JMF3086 (100 mg/kg) or vehicle (corn oil)
ﬁve days a week for two weeks.
2.6. Animal Model for Experimental Colorectal Cancer Liver Metastasis
Seven-week-old female NOD/SCIDmicewere anesthetized by a con-
tinuous ﬂow of 2%–3% isoﬂurane. To generate the mouse models with
liver metastases derived from human colorectal cancer cells, HT29-Lu-
ciferase-expressing cells (1 × 106) were suspended in 100 μL PBS and
injected into the spleen of mice. After a one-week recovery, the mice
were randomized into vehicle or treatment groups. JMF3086 was dis-
solved in corn oil and administered orally ﬁve days a week for two
weeks. Mice were then given endotoxin-free luciferase substrate and
photographed by IVIS imaging system (Xenogen) once a week. Mice
were sacriﬁced, and tumors from their spleens and liverswere collected,
weighed, and ﬁxed by formalin.
2.7. Animal Model for Colorectal Cancer Xenograft
Female BALB/c nude mice (6–7-week-old) were injected with 107
HCT116 cells (suspended in 0.1 mL PBS) in the rear left ﬂank. One
week after administration, mice carried 100 to 200 mm3 tumors were
treated with vehicle, oxaliplatin (2.5 mg/kg intraperitoneally once a
week), JMF3086 (10 mg/kg per oral once daily, ﬁve days per week), orusemodels. (A–G)Test compoundswere dissolved in cornoil and administered orallyﬁve
experimental design (upper panel). Representative whole colons were depicted, and the
ors and tumor sizes are graphed (lower panel). ⁎P b 0.05 and ⁎⁎P b 0.01 versus vehicle. (B)
ed areas are shown in the lower row. Scale bar: 250 μm. (C) Colon sections from CRCmice
her magniﬁcation images of the cells (original magniﬁcation: 400×; higher magniﬁcation:
from CRC mice is shown (lower panel). ⁎P b 0.05 and ⁎⁎P b 0.01 versus vehicle. (E) Colon
bar: 250 μm. (F) Gross pictures of terminal colons are shown, and arrowheads indicate
rs: 250 μm. The number of tumors and tumor sizes are graphed (middle panel). ⁎P b 0.05
6G antibodies (lower panel). Scale bar: 250 μm. (G) Colonic cytokines, chemokines, COX-
rmalized to GAPDH. Error bars represent SD. ##P b 0.01 versus control; ⁎P b 0.05 and
sates from colon tissues are shown. ##P b 0.01 versus control; ⁎P b 0.05 and ⁎⁎P b 0.01
experimental design (upper panel). Gross pictures of small intestine (middle panel) and
E (lower row of scale bars: 50 μm). (J) The number of tumors and tumor sizes of small
129T.-T. Wei et al. / EBioMedicine 10 (2016) 124–136a combination for two weeks, then sacriﬁced. Tumors were collected,
weighed, and ﬁxed by formalin.
2.8. Additional Methods
Detailed methodology is described in the Supplementary material.
3. Results
3.1. HMGR Is an Oncotarget of Colorectal Cancer
We examined HMGR activity in CRC patients and found an increase
in CRC tissues compared to the adjacent normal epithelium (Fig. 1A and
Table S1). The expression of HMGR protein in HCT116, RKO and SW480
CRC cells was examined, and high expression in HCT116 while low ex-
pression in SW480 cells was seen (Fig. 1B). To clarify the role of
HMGR in CRC, CRISPR technology was utilized to establish HMGR-
knockout stable clones in HCT116 cells. The apoptotic cells (suspension)
were removed during maintenance, and the anti-apoptotic protein,
MCL1 was found a signiﬁcant reduction (Fig. 1C, left). To verify the
anti-apoptotic role of HMGR, transient knockdown of HMGR by
shRNA was performed. Similar to CRISPR knockout cells, MCL1 was re-
duced while the apoptotic proteins, BAX and cleavage of pro-caspase-
3 were induced (Fig. 1C, right). To determine whether the cytotoxic ef-
fect observed in HMGR-depleted cells was due to the disruption of
mevalonate pathway, HMGR-knockout stable clones were treated
withmevalonate and subjected toMTT assay. Cell viability was reduced
in HMGR-knockout stable clones, E6 andH5, whereas this effect was re-
versed by the addition of mevalonate (Fig. 1D). This data indicated that
HMGR plays a pivotal role in the cell survival of CRC. On the other hand,
overexpression of HMGR in SW480 cells induced MCL1 and COX-II ex-
pression (Fig. 1E). These results demonstrate the oncogenic role of
HMGR in CRC cells.
The three statin hydroxamates, JMF3086, JMF3171, and JMF3173
were cytotoxic to CRC and various cancer cell lines (Fig. 1F–1G and
Table S2). Addition of mevalonate partially reversed JMF3086-induced
growth inhibition, but completely reversed that of lovastatin in
HCT116 cells (Fig. 1H), indicating that bothHMGR andHDAC inhibitions
contributed to the cytotoxic effect of JMF3086. JMF3086 induced apo-
ptosis by sub-G1 increase and cleavages of PARP and pro-caspase 3 in
HCT116 cells, in which increased pro-apoptotic BAX and decreased
anti-apoptotic BCL-2 were also seen (Fig. 1I–1K).
3.2. Genome-wide Analysis of JMF3086-targeted Genes in Colorectal Cancer
Cells
Chromatin immunoprecipitation (ChIP)-on-chip analysis revealed
the binding of H3K27-acetylation to N10,000 genes altered by
JMF3086. Those with two-fold downregulation or upregulation in log-
ratiowere selected and analyzed by GeneOntology (GO), which catego-
rized them into different biological functions; the most signiﬁcant ones
were apoptosis and inﬂammation. Ingenuity Pathways Analysis (IPA)
predicted their regulation by NR3C1 and NF-κB, respectively (Fig. 2A
and B). JMF3086 inhibited the binding of H3K27-Ac to the promotersFig. 4. Therapeutic effect of JMF3086 on colorectal cancer metastasis to the lung and liver in viv
lungs (scale bars: 5 mm) and their sections counterstained with H&E (scale bars: 250 μm) are
(upper right panel). ⁎⁎P b 0.01 versus vehicle. (B) HMGR and HDAC activities in cell lung
overview of the experimental design (upper left panel). The luciferase activity was detecte
quantitative data are shown (upper right panel). (D) Bioluminescence images of dissected
quantiﬁed (right panel). ⁎⁎P b 0.01 versus vehicle. (E) Gross pictures of spleen (upper panel)
(scale bar: 5 mm). Spleen and liver sections were counterstained with H&E in the lower ro
JMF3086 treatment. ⁎⁎P b 0.01 versus vehicle. (G) HCT116 cells treated with 30 μM JMF3086
matrigel plug assay was performed. We mixed 75 μL of conditioned media with 425 μL ma
sacriﬁced and dissected after 14 days. Quantiﬁcation of neovessel formation in matrigel plug
photographed. RPMI medium served as a negative control. ##P b 0.01 versus normoxia; ⁎⁎P b 0of genes controlling inﬂammation and proliferation, stemness of cancer,
and anti-apoptosis, and also reduced their mRNA expression. Converse-
ly, JM3086 increased the binding of H3K27-Ac to the gene promoters of
tumor suppressors and also increased their mRNA expression (Fig. 2C
and S1A–S1C). To further investigate these differential effects, the bind-
ing of acetyl-H3K27, CBP, HDAC1, and HDAC3 to promoters was exam-
ined by quantitative ChIP (qChIP) assays. JMF3086 reduced the binding
of acetyl-H3K27 and CBP to the promoters of TNF-α, CD166, COX-2,
BCL2, CXCL1, CXCL2, EpCAM, CD44, CyclinD1, and MCL1, but increased
the binding of HDAC1 and HDAC3 to the same promoters (Fig. 2D and
S1D). In contrast, JMF3086 increased the binding of acetyl-H3K27 and
CBP to the promoters of TIMP3, BMP2, and p53, but decreased the bind-
ing of HDAC1 and HDAC3 to the same promoters (Fig. 2D and S1D).3.3. JMF3086 and JMF3173 Are Effective Against Colorectal Cancer in the
AOM-DSS and ApcMin/+ Mouse Models
To investigate the in vivo anti-CRC effect of statin hydroxamates,
JMF3086 (100 mg/kg) or JMF3173 (100 mg/kg, 5 days per week for
3 weeks) was orally administered after CRC tumors were induced by
AOM and DSS (8th week) in mice (Fig. 3A). JMF compounds inhibited
the number and size of colon tumors, as well as symptoms (i.e. body
weight loss, diarrhea, and rectal bleeding), but not the shortening of
colon length (Fig. 3A and S2A–S2C). Microscopically, JMF compounds
inhibited AOM-DSS-induced colon adenocarcinoma with dysplasia, ex-
hibited surface tumor necrosis by H&E staining, and induced apoptosis
of CRC tumors, and also induced NR3C1mRNA expression in the tumors
(Fig. 3B–3D and S2D).
The tumormicroenvironment plays an important role in cancer pro-
gression and metastasis (Popivanova et al., 2009; Hanahan and
Weinberg, 2011). Tumor-associated macrophages (TAMs) and tumor-
associated neutrophils (TANs) are key components of tumormicroenvi-
ronment (Noy and Pollard, 2014; Mantovani, 2009). Therefore, IHCwas
performed in tumor section stainedwith themacrophagemarker F4/80,
neutrophil marker Ly-6G or anti-COX-II antibody (Erreni et al., 2011;
Jamieson et al., 2012) (Fig. 3E and S2E). The inﬁltrations ofmacrophages
and neutrophils as well as COX-II were abundant in AOM-DSS CRC and
were blocked by JMF compounds but not by statins or SAHA (Fig. 3E).
The anti-tumor effect of JMF3086 was superior to lovastatin plus
SAHA which was ineffective to block the inﬁltrations of macrophages
and neutrophils (Fig. 3F, bottom).
JMF compounds also reduced the mRNA expression of pro-inﬂam-
matory cytokines, chemokines, COX-II, and cyclin D1 in the colon (Fig.
3G). Both HMGR and HDAC activities elevated after AOM-DSS-induced
tumors were inhibited by JMF compounds, and the extent of inhibition
correlated with reductions in tumor number and size (Fig. 3H, S3A, and
S3B). In addition, the anti-cancer and anti-inﬂammatory effects of JMF
compounds were better than those of SAHA or statins (Fig. 3A–3F).
These indicated that both HDAC and HMGR contributed to the effects
of JMF compounds.
In addition to the AOM-DSS model, which is a representative of in-
ﬂammation-induced CRC, the effect of JMF3086 was examined in the
Min (multiple intestinal neoplasia) mouse model. The Min model is
the most commonly used transgenic CRC model, carrying a pointo. (A) Schematic overview of the experimental design (upper left panel). Gross pictures of
shown (middle panel). Quantitation of metastatic tumor nodules in mice are presented
lysates are shown. ##P b 0.01 versus control; ⁎⁎P b 0.01 versus vehicle. (C) Schematic
d by the IVIS imaging system three weeks after JMF3086 treatment (lower panel) and
spleens and livers from each mouse are shown (left panel). Synchronized images were
and liver (lower panel) are shown. The arrowheads indicate macroscopic tumor nodules
w (scale bars: 50 μm). (F) The number of liver nodules was graphed three weeks after
for 20 h were exposed to hypoxia for 4 h, then conditioned media was collected and the
trigel and 50 U heparin/mL was subcutaneously injected into nude mice, which were
s was estimated using Drabkin reagent kit 525. Matrigel plugs retrieved from mice were
.01 versus hypoxia.
130 T.-T. Wei et al. / EBioMedicine 10 (2016) 124–136mutation in the Apc gene and developing small intestinal and colon tu-
mors between ﬁve and eight weeks. Germline mutations of Apc in
humans will lead to colon polyposis and a cancer termed familialadenomatous polyposis (FAP) (Moser et al., 1990; Kettunen et al., 2003;
Shibata et al., 1997). JMF3086 (25 mg/kg or 50 mg/kg) inhibited tumor
formation in the small intestine and colon of ApcMin/+ mice (Fig. 3I–3J).
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132 T.-T. Wei et al. / EBioMedicine 10 (2016) 124–1363.4. JMF3086 Inhibits the In Vivo Lung and Liver Metastases of Colorectal
Cancer
Metastasis is a major cause of death from CRC, in which livers or
lungs are the most frequent sites (Villeneuve and Sundaresan, 2009;
Edwards et al., 2012). To examine the anti-metastatic activity of
JMF3086, HCT116 cells were intravenously injected into nude mice via
the tail vein. JMF3086 (100 mg/kg) reduced lung tumor nodules by
macroscopic observation (Fig. 4A), indicating an inhibition on lungme-
tastasis. Increased HMGR and HDAC activities inmetastatic lung tumors
were inhibited by JMF3086 (Fig. 4B), and the extent of inhibitions was
correlated with the effect of anti-lung metastasis (Fig. S4A and S4B).
The accumulation of JMF3086 in metastatic tumor cells in lungs was
also seen (Fig. S4C–S4E).
A liver metastasis model was established using HT29-Luciferase-ex-
pressing cells injected into the spleen of NOD/SCID mice, which were
photographed by the IVIS imaging system (Fig. 4C). Ex vivo biolumines-
cence in excised spleens and livers detected by IVIS showed that
JMF3086 inhibited liver metastasis and primary tumor growth in
spleens (Fig. 4C–4F and S4F). H&E staining further conﬁrmed theseﬁnd-
ings (Fig. 4E). JMF3086 did not inﬂuence body weight (Fig. S4G).
Angiogenesis is an essential step in tumor growth and metastasis
(Ellis and Hicklin, 2008). Conditioned medium from HCT116 cells
under hypoxia induced angiogenesis by matrigel plug assay in mice,
the effect of which was inhibited by JMF3086 (Fig. 4G), indicating its
anti-angiogenic effect.3.5. HMGR Enhances Colorectal Cancer Stemness and JMF3086 Inhibits
Stemness In Vitro and In Vivo
Stem cell expansion derived from the chronic inﬂammation of colon
which causes crypt injury and regeneration contributes to the genesis,
maintenance, recurrence, metastasis, and drug resistance of CRC (Eyler
and Rich, 2008; Pignalosa and Durante, 2012), and CD166, EpCAM,
CD44, and ALDH1 are putative surface markers (Huang and Wicha,
2008). CRC stem cells were generated by spheroid formation in suspen-
sion cultured from HCT116 cells (Mani et al., 2008) (Fig. S5A–S5F).
Knockdown of HMGR in HCT116 cells reduced the generation of spher-
oid formation and the proportion of CD44/CD166positive cells (Fig. 5A).
In contrast, overexpression of HMGR in SW480 cells enhanced the
spheroid formation and the proportion of CD44/CD166 positive cells
(Fig. 5B). Addition of mevalonate to HMGR-low-expressing LS-174 T
cells showed a similar result (Fig. 5C). These results indicate a role of
HMGR in CRC stemness.
The mRNA expression of CRC stemness markers was increased in
AOM-DSS-CRCmice and inhibited by JMF compounds (Fig. 5D). The for-
mation of colonospheres as well as ALDH+ population was inhibited by
JMF3086 (Fig. 5E). JMF3086 also suppressed the tumor growth and
tumor mass arising from colorectal CSCs in vivo, and inhibited the ex-
pression of CD166 and CD44 in the excised tumors (Fig. 5F–5G). Here,
JMF3086 was superior to lovastatin plus SAHA (Fig. 5F). These dataFig. 5. Role of HMG-CoA reductase in colorectal cancer stemcells and the effect of JMF3086 in vit
of HMGR knockdown on spheroids formation in HCT116 cells. Sphere-formation assay followin
panel). Scale bars: 100 μm. CD44+/CD166+ population inHCT116 spheroids was quantiﬁed by ﬂ
SW480 cells. Sphere-formation assay following HMGR overexpression in SW480 cells. Cell mo
population in SW480 spheroids was quantiﬁed by ﬂow cytometry (right panel). (C) Effect o
vehicle or mevalonate 0.2 mM during in vitro sphere-formation assay. Cell morphology was m
genes or markers were analyzed by qRT-PCR (right panel). (D) The mRNA expression of col
shown. ##P b 0.01 versus control; ⁎P b 0.05 and ⁎⁎P b 0.01 versus vehicle. (E) HCT116 colonosp
well plate. One day after plating, cells were treated with 30 μM JMF3086, lovastatin, SAHA, o
microscopy (upper left panel), and cell viability was measured by WST-1 assay (lower left pa
with 30 μM JMF3086 for 24 h, and ALDH activity was measured by ﬂow cytometry (right pan
(2 × 104 cells) were subcutaneously implanted into nude mice. The schematic overview of
200 mm3, vehicle (oil), JMF3086 (50 mg/kg), or the combination of lovastatin (50 mg/kg) a
measured every two days after JMF3086 treatment (upper right panel). ⁎P b 0.05 versus vehi
right panel) are shown. Scale bars: 5 mm. ⁎P b 0.05 versus vehicle. (G) Q-PCR analyzed the
versus vehicle.demonstrated the effectiveness of JMF3086 to inhibit the stemness of
CRC in vitro and in vivo.
3.6. JMF3086 Potentiated the Anti-cancer Effect of Oxaliplatin on Colorectal
Cancer In Vitro and In Vivo
Chemotherapy remains an important treatment option for metasta-
tic CRC, and drug combination is a rational approach to further improve
its efﬁcacy (Chibaudel et al., 2012; Meyerhardt and Mayer, 2005).
Therefore, we combined JMF3086 with oxaliplatin to examine their ef-
fect on CRC cells. Oxaliplatin-induced inhibition of cell viability in
HCT116 cells was potentiated by JMF3086, accompanied by enhanced
cleavages of PARP and pro-caspase 3, as well as an increase in sub-G1
population (Fig. 6A–6C).
We further examined the efﬁcacy of JMF3086 combined with
oxaliplatin in various mouse models. Oxaliplatin (2.5 mg/kg) plus
JMF3086 (10 mg/kg) showed enhanced effect on reducing the size
and weight of HCT116 xenograft tumors. Enhanced apoptosis in
xenografted tumors without inﬂuencing the body weight was seen
(Fig. 6D–6F, S6A, and S6B). The combination efﬁcacy (JMF3086
25 mg/kg and oxaliplatin 5 mg/kg) was also examined in the AOM-
DSS-CRC mouse model (Fig. 6G). The number and size of tumors at-
tenuated by oxaliplatin or JMF3086 alone were further reduced by
their combination (Fig. 6G, H, and S6C). Microscopically, AOM-DSS-
induced colon adenocarcinoma with dysplasia was recovered to
tumor necrosis in combination-treated mice (Fig. 6H). Hypoxia de-
tected by HIF-1α and hypoxyprobe seen in colon adenocarcinomas
was reduced by combination (Fig. 6I).
The combined effect of JMF3086with oxaliplatin on CRC livermetas-
tasis was also examined. Oxaliplatin (2.5 mg/kg) plus JMF3086
(10 mg/kg) showed better activity against tumors in spleen and
liver than either drug alone (Fig. 7A–7C and S6D). H&E staining fur-
ther conﬁrmed these ﬁndings (Fig. 7D), while body weight was not
affected (Fig. S6E).
4. Discussion
HMGR targeted by statins is the rate-limiting enzyme for the
mevalonate pathway to synthesize cholesterol and regulate protein
prenylation for cell growth (Thurnher et al., 2012). Since statins could
inhibit mevalonate metabolism, they have been tested as antitumor
drugs (Goldstein and Brown, 2015). Atorvastatin suppressed tumor ini-
tiation and growth in a transgenic model of MYC-induced hepatocellu-
lar carcinoma (HCC) as well as in human HCC-derived cell lines. These
effectswere blocked by the addition ofmevalonate (Cao et al., 2011), in-
dicating the correlation between HMGR inhibition and anti-cancer ef-
fects of statins. In this study, we further explored the role of HMGR as
an oncotarget in CRC. Its knockout or knockdown in HMGR-high-ex-
pressing CRC cells reduced the anti-apoptoic but increased apoptotic
proteins. However, its overexpression in HMGR-low-expressing CRC
cells induced anti-apoptotic protein and COX-II expressions. Additionro and in vivo. (A–C)HMGRmodulated spheroids formation in colon cancer cells. (A) Effect
g HMGR knockdown in HCT116 cells. Cell morphologywasmonitored bymicroscopy (left
ow cytometry (right panel). (B) Effect of HMGR overexpression on spheroids formation in
rphology was monitored by microscopy (left panel). Scale bars: 100 μm. CD44+/CD166+
f mevalonate on spheroids formation in LS-174T cells. LS-174T cells were treated with
onitored by microscopy (left panel). Scale bars: 100 μm. mRNA expression of stemness
orectal cancer stem cell markers in colon tissues from 11-week AOM-DSS-CRC mice are
heres were dissociated into single cells and plated at a density of 3000 cells/well in a 96-
r the combination of lovastatin and SAHA for 48 h. Cell morphology was monitored by
nel). Scale bars: 100 μm. ⁎⁎P b 0.01 versus basal; ##P b 0.01. HCT116 cells were incubated
el). The trapezoid (R1, R2) indicates the ALDH+ population. (F) HCT116 colonospheres
the experimental period follows (upper left panel). When the tumor volume reached
nd SAHA (50 mg/kg) were orally administered for two weeks. The tumor volume was
cle. A comparison of xenograft tumor weight (lower left panel) and gross picture (lower
mRNA expressions of CD166 and CD44, which were normalized to GAPDH. ⁎⁎P b 0.01
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Fig. 7. Effect of JMF3086 combinedwith oxaliplatin on colorectal cancermetastasis to the liver inmousemodels. (A) Schematic overview of the experimental design (upper panel). HT29-
Luciferase-expressing cellswere injected into the spleen of NOD/SCIDmice. After one-week recovery, oxaliplatin (2.5mg/kg) in combinationwith JMF3086 (10mg/kg)were administered
for an additional two weeks. Luciferase activity was detected three weeks after JMF3086 treatment by the IVIS imaging system (middle panel), which was then quantiﬁed (lower panel).
(B) Bioluminescence images of dissected livers (left panel) and spleens (right panel) fromeachmouse are shown. (C)Gross pictures of liver (left panel) and spleen (right panel) are shown,
with arrowheads indicating the macroscopic tumor nodules (scale bar: 5 mm). (D) Spleen and liver sections were counterstained with H&E (scale bars: 50 μm).
134 T.-T. Wei et al. / EBioMedicine 10 (2016) 124–136of mevalonate restored the cell viability of CRISPR knockout HMGR-
HCT116 cells. HMGR has been reported to be a critical regulator of
MYC phosphorylation, activation and tumorigenic properties in HCC
cells, and MYC positively regulated the expression of HMGR in esopha-
geal squamous carcinoma cells (Cao et al., 2011; Zhong et al., 2014).Fig. 6. Potentiation of JMF3086 on the effect of oxaliplatin in vitro and in colorectal cancermouse
the expression of apoptosis-related proteins, and on the cell cycle distribution are shown. (A) H
cell viability was assessed byMTT assay. ⁎P b 0.05 and ⁎⁎P b 0.01. (B) Total cell lysateswere prep
of JMF3086 combinedwith oxaliplatin onHCT116xenograftmodels. (D) Schematic overviewof
after drug treatment (lowerpanel). (E) Gross pictures of xenograft tumors are shown. Scale bar:
cells (original magniﬁcation: 1000×). (G–I) Effect of JMF3086 combined with oxaliplatin on A
(upper panel). Representative whole colons are depicted (middle panel), with arrowheads ind
graphed. ⁎⁎P b 0.01 versus vehicle (lower panel). (H) Colon sections were counterstained with
Scale bar: 250 μm. (I) Colon sections were immunostained with anti-HIF-1α and anti-pim
experiments are presented. Scale bar: 250 μm.Our previous study demonstrated that HDAC inhibition contributed
to the anticancer effect of statins (Lin et al., 2008). Combining anti-can-
cer drugs with different mechanisms is a rational approach to improve
efﬁcacy. JMF3086, synthesized to inhibit both HDACs and HMGR, ex-
hibits signiﬁcant beneﬁts above lovastatin plus SAHA. This advantagemodels in vivo. (A–C) Effect of JMF3086 combinedwith oxaliplatin on the cell viability, on
CT116 cells were treatedwith JMF3086, oxaliplatin, or their combination for 24 h, and then
ared, andWestern blotting was performed. (C) Flow cytometrywas analyzed. (D–F) Effect
the experimental design (upper panel). The tumor volumesweremonitored for twoweeks
1 cm. (F)Xenograft tumors fromCRCmicewere stained by TUNEL assay to detect apoptotic
OM-DSS-induced CRC mouse models. (G) Schematic overview of the experimental design
icating macroscopic polyps. Scale bars: 5 mm. The number of tumors and tumor sizes are
H&E, and high-magniﬁcation images of the black-boxed area are shown in the lower row.
onidazole (hypoxyprobe) antibodies. Representative images from three independent
135T.-T. Wei et al. / EBioMedicine 10 (2016) 124–136is like a two-in-one antibody which is better than twomonospeciﬁc an-
tibodies (Schaefer et al., 2011). Various polypharmacological molecules
dually inhibiting HDACs and other therapeutic targets have also been
developed and provide an impetus to develop more anti-cancer treat-
ments (Falkenberg and Johnstone, 2014). Evading apoptosis is a hall-
mark of cancer (Hanahan and Weinberg, 2011), where apoptosis
induction represents one therapeutic strategy (Cotter, 2009). Anti-apo-
ptotic genes such as BCL2 and MCL1 were down-regulated by JMF3086
from genome-wide ChIP-on-chip and Q-PCR analyses, and JMF3086 did
induce apoptosis in HCT116 cells and tumors of CRCmice, indicating the
contribution of apoptosis induction to the therapeutic effect of JMF3086
on CRC. NR3C1, which is a glucocorticoid receptor, was predicted to be
induced by JMF3086 from GO and IPA analyses. It induced apoptotic
cell death via decreasing the expression of anti-apoptotic proteins
such as BCL2 and MCL1, and/or via inducing the expression of pro-apo-
ptotic proteins such as BCL-2-like apoptosis initiator-11 (BCL2L11)
(Schlossmacher et al., 2011). JMF compounds did induce NR3C1
mRNA expression in CRC mice, indicating its contribution to apoptosis.
The tumor microenvironment consisting of cancer cells, stromal tis-
sue, blood vessels, immune cells, ﬁbroblasts, bone marrow-derived in-
ﬂammatory cells, lymphocytes and the extracellular matrix, plays a
critical role in cancer development, progression and metastasis
(Popivanova et al., 2009; Hanahan andWeinberg, 2011). Clinical studies
have indicated its association with poor prognosis in patients with var-
ious human cancers (Erreni et al., 2011; Gregory and Houghton, 2011).
Tumor-associated macrophages (TAMs) are key components of tumor
microenvironment (Noy and Pollard, 2014). They can produce growth
factors, cytokines, chemokines and matrix metalloproteases (MMP) to
promote cancer progression, metastasis, angiogenesis and
lymphangiogenesis (Qian and Pollard, 2010). Tumor-associated neutro-
phils (TANs) acting through the production of cytokines/chemokines
and the recruitment of TAMs to the tumor sites also play a role in
tumor microenvironment (Mantovani, 2009; Nathan, 2006). In this
study, both inﬁltrations of macrophages and neutrophils occurring in
AOM-DSS mouse models were blocked by JMF compounds but not by
statins, SAHA or lovastatin plus SAHA (Fig. 3E and F), probably
explaining the better efﬁcacy of JMF3086 than lovastatin plus SAHA in
treating AOM-DSS CRC. However, whether TAMs and TANs affected by
JMF3086 are beyond its inhibitions on HMGR and HDAC remains to be
investigated.
Metastasis is the major cause of CRC-related deaths, and livers or
lungs are the primary organs of metastasis (Villeneuve and
Sundaresan, 2009; Edwards et al., 2012). JMF3086 showed signiﬁcant
efﬁcacy in inhibitingmetastasis and potentiated the effect of oxaliplatin.
The mechanism may involve the inhibition on angiogenesis (Fig. 4G).
Furthermore, combination of JMF3086 with oxaliplatin reduced the
hypoxic region and downregulated HIF-1α expression in vivo (Fig. 6I).
Stemness of cancer cellsmay play a role in the genesis,maintenance, re-
currence, metastasis, and drug resistance of CRC (Eyler and Rich, 2008;
Pignalosa and Durante, 2012). Loss of CSC populations or stem-like
properties could hinder the metastatic spread of the tumor
(Pattabiraman and Weinberg, 2014). Stem cell expansion was derived
from chronic inﬂammation causing damage and regeneration of crypt
and release of cytokines, which maintain and regulate cancer stem-
cell niche (Carpentino et al., 2009; Liu and Wicha, 2010). JMF3086 at-
tenuated the cytokines in CRC mice and inhibited the expression of
stemness-related genes. We provide direct evidences to demon-
strate that HMGR enhances the stemness of CRC cells, and JMF3086
inhibited the growth of colonospheres and colonosphere-derived
xenografts more than lovastatin plus SAHA. Statins was reported to
lower cytokines levels to target CSCs and inhibited tumor growth
as well as metastasis (Ridker et al., 2005), and HDAC inhibitor re-
duced the stemness of CRC cells (Kodach et al., 2011; Sikandar et
al., 2010). These indicate that dual HMGR-HDAC inhibitor
JMF3086-induced inhibitions on stemness and metastasis contribute
to its anti-CRC effect.In summary, our ﬁndings indicate that HMGR is an oncotarget to en-
hance survival and stemness of CRC. The dual HMGR-HDAC inhibitor,
JMF3086, exhibits promising preclinical efﬁcacy against CRC and its me-
tastasis in mouse models. It also potentiates the effect of the standard
chemotherapy drug oxaliplatin. Therefore, JMF3086 is a promising
lead compound for CRC treatment.
Grant Support
This work was supported by a research grant from the National
Science Council, Taiwan and the Institute of Biomedical Sciences, Acade-
mia Sinica (IBMS-CRC103-P02).
Conﬂicts of Interest
The authors disclose no conﬂicts of interest.
Author Contributions
Study concept and design: Chen CC
Acquisition of data:Wei TT, Lin YT, ChenWS, Luo P, Lin YH, ChenNW
Analysis and interpretation of data: Wei TT, Lin YT, Shun CT, Lin YH,
Chen NW
Drafting of the manuscript: Wei TT, Chen CC
Critical revision of themanuscript for important intellectual content:
Chen CC, Lin YC
Statistical analysis: Wei TT, Lin YT, Lin YH, Chen NW
Obtained funding: Chen CC
Technical or material support: Fang JM, Chen JB, Chen NW, Yang KC,
Wu MS, Chang LC, Tai KY, Liang JT
Study supervision: Chen CC
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.07.019.
References
Cao, Z., Fan-Minogue, H., Bellovin, D.I., Yevtodiyenko, A., Arzeno, J., Yang, Q., Gambhir, S.S.,
Felsher, D.W., 2011. MYC phosphorylation, activation, and tumorigenic potential in
hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res. 71,
2286–2297.
Carpentino, J.E., Hynes, M.J., Appelman, H.D., Zheng, T., Steindler, D.A., Scott, E.W., Huang,
E.H., 2009. Aldehyde dehydrogenase-expressing colon stem cells contribute to tu-
morigenesis in the transition from colitis to cancer. Cancer Res. 69, 8208–8215.
Chen, J.B., Chern, T.R., Wei, T.T., Chen, C.C., Lin, J.H., Fang, J.M., 2013. Design and synthesis
of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglu-
taryl coenzyme a reductase for cancer treatment. J. Med. Chem. 56, 3645–3655.
Chibaudel, B., Tournigand, C., Andre, T., de Gramont, A., 2012. Therapeutic strategy in
unresectable metastatic colorectal cancer. Ther. Adv. Med. Oncol. 4, 75–89.
Chou, C.W., Wu, M.S., Huang, W.C., Chen, C.C., 2011. HDAC inhibition decreases the ex-
pression of EGFR in colorectal cancer cells. PLoS One 6, e18087.
Cotter, T.G., 2009. Apoptosis and cancer: the genesis of a research ﬁeld. Nat. Rev. Cancer 9,
501–507.
Edwards, M.S., Chadda, S.D., Zhao, Z., Barber, B.L., Sykes, D.P., 2012. A systematic review of
treatment guidelines for metastatic colorectal cancer. Color. Dis. 14, e31–e47.
Ellis, L.M., Hicklin, D.J., 2008. VEGF-targeted therapy: mechanisms of anti-tumour activity.
Nat. Rev. Cancer 8, 579–591.
Erreni, M., Mantovani, A., Allavena, P., 2011. Tumor-associated macrophages (TAM) and
inﬂammation in colorectal cancer. Cancer Microenviron. 4, 141–154.
Eyler, C.E., Rich, J.N., 2008. Survival of the ﬁttest: cancer stem cells in therapeutic resis-
tance and angiogenesis. J. Clin. Oncol. 26, 2839–2845.
Falkenberg, K.J., Johnstone, R.W., 2014. Histone deacetylases and their inhibitors in cancer,
neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13, 673–691.
Freed-Pastor, W.A., Mizuno, H., Zhao, X., Langerod, A., Moon, S.H., Rodriguez-Barrueco, R.,
Barsotti, A., Chicas, A., Li, W., Polotskaia, A., Bissell, M.J., Osborne, T.F., Tian, B., Lowe,
S.W., Silva, J.M., Borresen-Dale, A.L., Levine, A.J., Bargonetti, J., Prives, C., 2012. Mutant
p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148,
244–258.
Goldstein, J.L., Brown, M.S., 2015. A century of cholesterol and coronaries: from plaques to
genes to statins. Cell 161, 161–172.
Gregory, A.D., Houghton, A.M., 2011. Tumor-associated neutrophils: new targets for can-
cer therapy. Cancer Res. 71, 2411–2416.
136 T.-T. Wei et al. / EBioMedicine 10 (2016) 124–136Hanahan, D., Weinberg, R.A., 2011. Hallmarks of cancer: the next generation. Cell 144,
646–674.
Huang, E.H., Wicha, M.S., 2008. Colon cancer stem cells: implications for prevention and
therapy. Trends Mol. Med. 14, 503–509.
Jamieson, T., Clarke, M., Steele, C.W., Samuel, M.S., Neumann, J., Jung, A., Huels, D.,
Olson, M.F., Das, S., Nibbs, R.J., Sansom, O.J., 2012. Inhibition of CXCR2 profoundly
suppresses inﬂammation-driven and spontaneous tumorigenesis. J. Clin. Invest.
122, 3127–3144.
Kettunen, H.L., Kettunen, A.S., Rautonen, N.E., 2003. Intestinal immune responses in wild-
type and Apcmin/+ mouse, a model for colon cancer. Cancer Res. 63, 5136–5142.
Kodach, L.L., Jacobs, R.J., Voorneveld, P.W., Wildenberg, M.E., Verspaget, H.W., van Wezel,
T., Morreau, H., Hommes, D.W., Peppelenbosch, M.P., van Den Brink, G.R., Hardwick,
J.C., 2011. Statins augment the chemosensitivity of colorectal cancer cells inducing
epigenetic reprogramming and reducing colorectal cancer cell ‘stemness’ via the
bone morphogenetic protein pathway. Gut 60, 1544–1553.
Lin, Y.C., Lin, J.H., Chou, C.W., Chang, Y.F., Yeh, S.H., Chen, C.C., 2008. Statins increase p21
through inhibition of histone deacetylase activity and release of promoter-associated
HDAC1/2. Cancer Res. 68, 2375–2383.
Liu, S., Wicha, M.S., 2010. Targeting breast cancer stem cells. J. Clin. Oncol. 28, 4006–4012.
Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M., Reinhard, F.,
Zhang, C.C., Shipitsin, M., Campbell, L.L., Polyak, K., Brisken, C., Yang, J., Weinberg, R.A.,
2008. The epithelial-mesenchymal transition generates cells with properties of stem
cells. Cell 133, 704–715.
Mantovani, A., 2009. The yin-yang of tumor-associated neutrophils. Cancer Cell 16,
173–174.
Meyerhardt, J.A., Mayer, R.J., 2005. Systemic therapy for colorectal cancer. N. Engl. J. Med.
352, 476–487.
Minder, C.M., Blaha, M.J., Horne, A., Michos, E.D., Kaul, S., Blumenthal, R.S., 2012. Evidence-
based use of statins for primary prevention of cardiovascular disease. Am. J. Med. 125,
440–446.
Moser, A.R., Pitot, H.C., Dove, W.F., 1990. A dominant mutation that predisposes to multi-
ple intestinal neoplasia in the mouse. Science 247, 322–324.
Nathan, C., 2006. Neutrophils and immunity: challenges and opportunities. Nat. Rev.
Immunol. 6, 173–182.
Noy, R., Pollard, J.W., 2014. Tumor-associatedmacrophages: frommechanisms to therapy.
Immunity 41, 49–61.
Pattabiraman, D.R., Weinberg, R.A., 2014. Tackling the cancer stem cells - what challenges
do they pose? Nat. Rev. Drug Discov. 13, 497–512.
Pignalosa, D., Durante, M., 2012. Overcoming resistance of cancer stem cells. Lancet Oncol.
13, e187–e188.
Popivanova, B.K., Kostadinova, F.I., Furuichi, K., Shamekh, M.M., Kondo, T., Wada, T.,
Egashira, K., Mukaida, N., 2009. Blockade of a chemokine, CCL2, reduces chronic coli-
tis-associated carcinogenesis in mice. Cancer Res. 69, 7884–7892.Poynter, J.N., Gruber, S.B., Higgins, P.D., Almog, R., Bonner, J.D., Rennert, H.S., Low, M.,
Greenson, J.K., Rennert, G., 2005. Statins and the risk of colorectal cancer. N. Engl.
J. Med. 352, 2184–2192.
Qian, B.Z., Pollard, J.W., 2010. Macrophage diversity enhances tumor progression andme-
tastasis. Cell 141, 39–51.
Ridker, P.M., Cannon, C.P., Morrow, D., RIFAI, N., Rose, L.M., Mccabe, C.H., Pfeffer, M.A.,
Braunwald, E., 2005. C-reactive protein levels and outcomes after statin therapy. N.
Engl. J. Med. 352, 20–28.
Schaefer, G., Haber, L., Crocker, L.M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A.,
Lee, C.V., Stawicki, S., Clark, R., Fields, C., Lewis Phillips, G.D., Prell, R.A., Danilenko,
D.M., Franke, Y., Stephan, J.P., Hwang, J., Wu, Y., Bostrom, J., Sliwkowski, M.X., Fuh,
G., Eigenbrot, C., 2011. A two-in-one antibody against HER3 and EGFR has superior
inhibitory activity compared with monospeciﬁc antibodies. Cancer Cell 20, 472–486.
Schlossmacher, G., Stevens, A., White, A., 2011. Glucocorticoid receptor-mediated apopto-
sis: mechanisms of resistance in cancer cells. J. Endocrinol. 211, 17–25.
Semenza, G.L., 2003. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721–732.
Shibata, H., Toyama, K., Shioya, H., Ito, M., Hirota, M., Hasegawa, S., Matsumoto, H.,
Takano, H., Akiyama, T., Toyoshima, K., Kanamaru, R., Kanegae, Y., Saito, I.,
Nakamura, Y., Shiba, K., Noda, T., 1997. Rapid colorectal adenoma formation initiated
by conditional targeting of the Apc gene. Science 278, 120–123.
Sikandar, S., Dizon, D., Shen, X., Li, Z., Besterman, J., Lipkin, S.M., 2010. The class I HDAC
inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating
cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. Oncotarget 1,
596–605.
Simon, M.S., Rosenberg, C.A., Rodabough, R.J., Greenland, P., Ockene, I., Roy, H.K., Lane,
D.S., Cauley, J.A., Khandekar, J., 2012. Prospective analysis of association between
use of statins or other lipid-lowering agents and colorectal cancer risk. Ann.
Epidemiol. 22, 17–27.
Thurnher, M., Nussbaumer, O., Gruenbacher, G., 2012. Novel aspects of mevalonate path-
way inhibitors as antitumor agents. Clin. Cancer Res. 18, 3524–3531.
Ullman, T.A., Itzkowitz, S.H., 2011. Intestinal inﬂammation and cancer. Gastroenterology
140, 1807–1816.
Villeneuve, P.J., Sundaresan, R.S., 2009. Surgical management of colorectal lung metasta-
sis. Clin. Colon Rectal Surg. 22, 233–241.
Yang, P.M., Lin, Y.T., Shun, C.T., Lin, S.H., Wei, T.T., Chuang, S.H., Wu, M.S., Chen, C.C., 2013.
Zebularine inhibits tumorigenesis and stemness of colorectal cancer via p53-depen-
dent endoplasmic reticulum stress. Sci. Rep. 3, 3219.
Yuan, T.L., Cantley, L.C., 2008. PI3K pathway alterations in cancer: variations on a theme.
Oncogene 27, 5497–5510.
Zhong, C., Fan, L., Yao, F., Shi, J., Fang, W., Zhao, H., 2014. HMGCR is necessary for the
tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc. Tu-
mour Biol. 35, 4123–4129.
